Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow First Trust: 

Search by Ticker, Keyword or CUSIP       
 
 
First Trust NYSE Arca Biotechnology Index Fund (FBT)
Investment Objective/Strategy - The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology IndexSM.
There can be no assurance that the Fund's investment objectives will be achieved.
  • The NYSE Arca Biotechnology IndexSM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
  • Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
  • The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent approximately equal weight in the index.
Fund Overview
TickerFBT
Fund TypeBiotechnology
Investment AdvisorFirst Trust Advisors L.P.
Investor Servicing AgentBank of New York Mellon
CUSIP33733E203
Intraday NAVFBTIV
Fiscal Year-End12/31
ExchangeNYSE Arca
Inception6/19/2006
Inception Price$20.00
Inception NAV$20.00
Rebalance FrequencyQuarterly
Gross Expense Ratio*0.60%
Net Expense Ratio*0.60%
* As of 12/31/2013
Expenses are capped contractually at 0.60% per year, at least until April 30, 2014.
Current Fund Data (as of 4/22/2014)
Closing NAV1$75.66
Closing Share Price2$75.64
Bid/Ask Midpoint$75.67
Bid/Ask Premium0.01%
Total Net Assets$1,112,209,686
Outstanding Shares14,700,002
Daily Volume178,662
Average 30-Day Daily Volume286,137
Closing Share Price 52-Week High/Low$87.45 / $55.10
Closing NAV 52-Week High/Low$87.39 / $55.04
Number of Holdings20
Fund Characteristics (as of 3/31/2014)3
Median Market Cap.$7,898
Maximum Market Cap.$111,033
Minimum Market Cap.$1,094
Price/Earnings34.23
Price/Book6.71
Price/Cash Flow26.43
Price/Sales9.51
Top Holdings (as of 4/22/2014)
Holding Percent
Nektar Therapeutics 5.36%
Incyte Corporation 5.31%
Illumina, Inc. 5.23%
InterMune, Inc. 5.22%
Vertex Pharmaceuticals Incorporated 5.10%
Biogen Idec Inc. 5.05%
Regeneron Pharmaceuticals, Inc. 5.03%
Alexion Pharmaceuticals, Inc. 4.99%
Gilead Sciences, Inc. 4.99%
Immunogen, Inc. 4.99%

Holdings are subject to change.

Bid/Ask Midpoint and NAV History (Since Inception)
Past performance is not indicative of future results.
Bid/Ask Midpoint vs. NAV (as of 3/31/2014)
Number of Days Bid/Ask Midpoint Above NAV
Quarter Ended 0-49
Basis Points
50-99
Basis Points
100-199
Basis Points
>=200
Basis Points
3/31/2014 44 0 0 0
12/31/2013 54 0 0 0
9/30/2013 55 0 0 0
6/30/2013 50 0 0 0
Number of Days Bid/Ask Midpoint Below NAV
Quarter Ended 0-49
Basis Points
50-99
Basis Points
100-199
Basis Points
>=200
Basis Points
3/31/2014 17 0 0 0
12/31/2013 10 0 0 0
9/30/2013 9 0 0 0
6/30/2013 14 0 0 0

The price used to calculate market return is determined by using the midpoint between the highest bid and the lowest offer on the stock exchange, on which shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated.

Month End Performance (as of 3/31/2014)
  3 Mos YTD 1 Year 3 Year 5 Year 10 Year Since
Fund
Inception4
Fund Performance *
NAV 10.97% 10.97% 41.17% 23.03% 31.52% N/A 19.04%
After Tax Held 10.97% 10.97% 41.17% 23.03% 31.52% N/A 18.98%
After Tax Sold 6.21% 6.21% 23.30% 18.33% 26.48% N/A 16.05%
Market Price 10.98% 10.98% 41.11% 22.99% 31.61% N/A 19.04%
Index Performance **
NYSE Arca Biotechnology Index 11.02% 11.02% 41.75% 23.72% 32.26% 17.29% 19.74%
NASDAQ Biotech Index 4.25% 4.25% 48.26% 33.72% 29.82% 12.53% 17.56%
S&P Composite 1500 Health Care Index 5.39% 5.39% 29.45% 23.06% 22.36% 9.41% 11.45%
S&P 500 Index 1.81% 1.81% 21.86% 14.66% 21.16% 7.42% 7.72%
Quarter End Performance (as of 3/31/2014)
  3 Mos YTD 1 Year 3 Year 5 Year 10 Year Since
Fund
Inception4
Fund Performance *
NAV 10.97% 10.97% 41.17% 23.03% 31.52% N/A 19.04%
After Tax Held 10.97% 10.97% 41.17% 23.03% 31.52% N/A 18.98%
After Tax Sold 6.21% 6.21% 23.30% 18.33% 26.48% N/A 16.05%
Market Price 10.98% 10.98% 41.11% 22.99% 31.61% N/A 19.04%
Index Performance **
NYSE Arca Biotechnology Index 11.02% 11.02% 41.75% 23.72% 32.26% 17.29% 19.74%
NASDAQ Biotech Index 4.25% 4.25% 48.26% 33.72% 29.82% 12.53% 17.56%
S&P Composite 1500 Health Care Index 5.39% 5.39% 29.45% 23.06% 22.36% 9.41% 11.45%
S&P 500 Index 1.81% 1.81% 21.86% 14.66% 21.16% 7.42% 7.72%
3-Year Statistics (as of 3/31/2014)
  Standard Deviation Alpha Beta Sharpe Ratio Correlation
FBT 23.89% 6.79 1.17 0.97 0.61
NASDAQ Biotech Index 18.87% 18.47 0.87 1.63 0.57
S&P Composite 1500 Health Care Index 11.44% 10.15 0.78 1.85 0.85
S&P 500 Index 12.47% --- 1.00 1.13 1.00
Standard Deviation is a measure of price variability (risk). Alpha is an indication of how much an investment outperforms or underperforms on a risk-adjusted basis relative to its benchmark.Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure of excess reward per unit of volatility. Correlation is a measure of the similarity of performance.

*Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost.

After Tax Held returns represent return after taxes on distributions. Assumes shares have not been sold. After Tax Sold returns represent the return after taxes on distributions and the sale of fund shares. Returns do not represent the returns you would receive if you traded shares at other times. Market Price returns are based on the midpoint of the bid/ask spread. Returns are average annualized total returns, except those for periods of less than one year, which are cumulative. The fund's performance reflects fee waivers and expense reimbursements, absent which performance would have been lower.

After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

**Performance information for the NYSE Arca Biotechnology Index is for illustrative purposes only and does not represent actual fund performance. The Index does not charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown. Indexes are unmanaged and an investor cannot invest directly in an index.

The gross expense ratio for this fund is 0.60%. Expenses are capped contractually at 0.60% per year, at least until April 30, 2014.

The NASDAQ Biotech Index includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.

The S&P Composite 1500 Health Care Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index.

The S&P 500 Index is an unmanaged index of 500 stocks used to measure large-cap U.S. stock market performance.

Footnotes
1 The NAV represents the fund's net assets (assets less liabilities) divided by the fund's shares outstanding.
2 Fund shares are purchased and sold on an exchange at their share price rather than net asset value (NAV), which may cause the shares to trade at a price greater than NAV (premium) or less than NAV (discount).
3 All market capitalization numbers are in USD$ Millions.
4 Inception Date is 6/19/2006
Downloads and Links to Recently Posted Fund Information

You should consider the fund's investment objectives, risks, and charges and expenses carefully before investing. You can download a prospectus or summary prospectus, or contact First Trust Portfolios L.P. at 1-800-621-1675 to request a prospectus or summary prospectus which contains this and other information about the fund. The prospectus or summary prospectus should be read carefully before investing.

ETF Characteristics

The fund lists and principally trades its shares on the NYSE Arca, Inc.

The fund's return may not match the return of the NYSE Arca Biotechnology Index.  Securities held by the fund will generally not be bought or sold in response to market fluctuations.

The fund may not be fully invested at times. Investors buying or selling fund shares on the secondary market may incur customary brokerage commissions. Market prices may differ to some degree from the net asset value of the shares. Investors who sell fund shares may receive less than the share's net asset value. Shares may be sold throughout the day on the exchange through any brokerage account. However, unlike mutual funds, shares may only be redeemed directly from the fund by authorized participants, in very large creation/redemption units.

Risk Considerations

The fund's shares will change in value, and you could lose money by investing in the fund. One of the principal risks of investing in the fund is market risk. Market risk is the risk that a particular stock owned by the fund, fund shares or stocks in general may fall in value.

The fund may invest in small capitalization and mid capitalization companies. Such companies may experience greater price volatility than larger, more established companies.

The fund is concentrated in stocks of companies in the biotechnology sector. You should be aware that an investment in a portfolio which is concentrated in a particular sector involves additional risks, including limited diversification. The companies engaged in the biotechnology sector are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to rapid obsolescence.

The fund is classified as "non-diversified." A non-diversified fund generally may invest a larger percentage of its assets in the securities of a smaller number of issuers. As a result, the fund may be more susceptible to the risks associated with these particular companies, or to a single economic, political or regulatory occurrence affecting these companies.

The NYSE Arca Biotechnology IndexSM is a trademark of NYSE Euronext or its affiliates ("NYSE Euronext") and is licensed for use by First Trust. The fund is not sponsored or endorsed by NYSE Euronext. NYSE Euronext makes no representation or warranty, express or implied, to the owners of the fund or any member of the public regarding the advisability of investing in the fund or the ability of the fund to track the performance of the various sectors represented in the stock market. NYSE Euronext has no obligation to take the needs of the owners of the fund into consideration in determining, composing or calculating the index. NYSE Euronext is not responsible for and has not participated in any determination or calculation made with respect to issuance or redemption of the fund.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value
 
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan
Copyright © 2014 All rights reserved.